feature photo

Research Areas

HIV Treatment

The IMPAACT HIV Treatment Scientific Committee aims to evaluate the pharmacokinetics (PK), safety, and drug interactions of new and existing antiretroviral (ARV) agents and formulations leading to optimal dosing and licensing for HIV-infected infants, children, adolescents, and pregnant/postpartum women. Despite licensure of more than 30 ARVs in adults, most of the new ARVs have not been evaluated for PK, safety and dosing in pregnant women, children, and especially newborns and infants. Priorities include evaluation of PK properties of ARVs and related drugs during pregnancy and postpartum as well as PK and safety of ARV and related drugs for infants, children, and adolescents.

Committee Contacts

Chair: Elaine Abrams
Vice-Chair: Ted Ruel
Operations Center: Sarah Bradford and Katie McCarthy

Presentations

2016 IMPAACT Annual Meeting Treatment Committee presentations

2015 IMPAACT Annual Meeting Treatment Committee presentation

Studies Within This Research Area

IMPAACT 2017
IMPAACT 2014
IMPAACT 2010
IMPAACT 2007
IMPAACT 2006
IMPAACT P1110
IMPAACT P1106
IMPAACT P1102/START
IMPAACT P1101
IMPAACT P1097
IMPAACT P1093
IMPAACT P1092
IMPAACT P1090
IMPAACT P1070
IMPAACT P1066
IMPAACT P1060
IMPAACT P1026s

 

 

 

 

 

 

 

 

 

 

 

 

Funded by the National Institute of Allergy and Infectious Diseases, the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health of the US National Institutes of Health, US Department of Health and Human Services.